Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases. (OCEAN-ILD)
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases: a Prospective Observational Study.
Studie Overzicht
Toestand
Conditie
- Beroepsmatige blootstelling
- Overgevoeligheid Pneumonitis
- Blootstelling aan milieuverontreiniging
- Idiopathische longfibrose (IPF)
- ILD
- Interstitiële longziekte als gevolg van systemische ziekte (aandoening)
- Progressieve longfibrose
- Beroepsmatige blootstelling
- Blootstelling aan chemische vervuiling, beroepsmatig
- Blootstelling aan luchtvervuiling van huishoudens
- Interstitiële longziekte als gevolg van systemische ziekten (telomeerbiologiestoornis)
- ILD Progressie en Blootstelling aan Binnenmilieurisico's
- ILD Progressie en Blootstelling aan Buitenluchtverontreinigende Stoffen
Interventie / Behandeling
Gedetailleerde beschrijving
Interstitial lung diseases (ILDs) represent a diverse group of parenchymal lung disorders associated with significant morbidity and mortality, with few FDA-approved treatment options available. While certain subtypes-such as hypersensitivity pneumonitis and pneumoconiosis-are clearly linked to environmental exposures, the role of such exposures in other ILD forms remains less well defined. Recent evidence has showed that most patients across all types of ILD had potentially relevant inhalational exposures. Exposures were associated with worse transplant-free survival. Thus, identification and avoidance of exposures represent actionable targets in ILD management.
Different questionnaires have been proposed to evaluate occupational and environmental exposure in such patients. However, to date, there aren't standardized and validated questionnaires addressing exposures in patients with ILD. Interstitial lung diseases (ILDs) represent a diverse group of parenchymal lung disorders associated with significant morbidity and mortality, with few FDA-approved treatment options available. While certain subtypes-such as hypersensitivity pneumonitis and pneumoconiosis-are clearly linked to environmental exposures, the role of such exposures in other ILD forms remains less well defined. Recent evidence has showed that most patients across all types of ILD had potentially relevant inhalational exposures. Exposures were associated with worse transplant-free survival. Thus, identification and avoidance of exposures represent actionable targets in ILD management.
Different questionnaires have been proposed to evaluate occupational and environmental exposure in such patients. However, to date, there aren't standardized and validated questionnaires addressing exposures in patients with ILD. Moreover, frequency of exposure across different types of ILDs are not well defined in Italy.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
Italy
-
Rozzano, Italy, Italië, 20089
- Humanitas Research Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Eligible participants will be identified during routine ILD outpatient visits and enrolled after written informed consent. Baseline data collection will occur at the time of enrollment.
Diagnostic consistency will be ensured through multidisciplinary discussion (MDD). The contribution of exposure history to diagnostic refinement and additional testing will be systematically recorded.
Data will be prospectively collected using a standardised CRF at baseline and every 6 months (±2 months), in line with clinical practice.
A structured questionnaire assessing environmental and occupational exposures will be:
- Administered at baseline
- Re-administered at each follow-up visit
Exposure domains will include:
- Occupational exposures (dusts, fibres, chemicals)
- Domestic exposures (mould, animals, biomass)
- Hobbies and recreational exposures
- Drug-related exposures Exposure relevance will be evaluated during MDD.
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years old
- Any gender
- Any race
- Ability to give informed consent according to ICH/EU GCP, and national/local regulations.
- New diagnosis of ILD according to classified according to American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias
Exclusion Criteria:
- Sarcoidosis
- Primary diagnosis of COPD and/or Asthma
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
ILD Patients Undergoing Exposure Assessment
Eligible participants will be adults (≥18 years) with new diagnosis of ILD according to classified according to American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
|
standard interview to detect relevant exposures
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of any exposure (environmental and/or occupational) in ILD patients.
Tijdsspanne: 5 years
|
to assess the frequency of environmental and/or occupational exposures among patients with newly diagnosed ILD
|
5 years
|
|
Use of a standardized questionnaire in all the centers
Tijdsspanne: 5 years
|
To standardise exposure assessment through a structured questionnaire across participating centres
|
5 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The prevalence of environmental and/or occupational exposures in patients diagnosed with IPF, HP or other forms of ILD
Tijdsspanne: 5 years
|
To compare the frequency of any exposure among patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and other forms of ILD
|
5 years
|
|
All-cause mortality
Tijdsspanne: 5 years
|
All-cause mortality
|
5 years
|
|
Development of a progressive pulmonary fibrosis (PPF) phenotype.
Tijdsspanne: 5 years
|
To evaluate the percentage of patients developing a progressive pulmonary fibrosis (PPF) phenotype in the "exposure" and "no exposure" group.
|
5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Francesco Amati, MD, Humanitas Research Hospital IRCCS, Rozzano-Milan
Publicaties en nuttige links
Algemene publicaties
- Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 21;27(150):180076. doi: 10.1183/16000617.0076-2018. Print 2018 Dec 31.
- Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
- Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.
- Morell F, Villar A, Montero MA, Munoz X, Colby TV, Pipvath S, Cruz MJ, Raghu G. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med. 2013 Nov;1(9):685-94. doi: 10.1016/S2213-2600(13)70191-7. Epub 2013 Oct 21.
- Lee CT, Adegunsoye A, Chung JH, Ventura IB, Jablonski R, Montner S, Vij R, Hines SE, Strek ME. Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest. 2021 Jul;160(1):209-218. doi: 10.1016/j.chest.2021.02.026. Epub 2021 Feb 20.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- ILD
- Idiopathische longfibrose
- Interstitiële longziekte
- Beroepsmatige blootstelling
- extrinsieke allergische alveolitis
- Progressieve longfibrose
- Exposure to Environmental Pollution
- Exposure to Chemical Pollution, Occupational
- Exposure to household air pollution
- Hypersensitivity pneumonitis
- chronic hypersensitivity pneumonitis
- acute hypersensitivity pneumonitis
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Prot. Nr. 57/26
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .